# US 2024/0254466 A1 · Engineered class 2, type v repressor systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254466 A1
- Document ID: US20240254466A1
- Status: Published application
- Kind: A1
- Application number: 18/612,882
- Filed: 2024-03-21
- Published: 2024-08-01
- Earliest claimed: 2021-09-21
- Assignees: Scribe Therapeutics Inc.
- Applicants: Scribe Therapeutics Inc.
- Inventors: Jason FERNANDES; Ross WHITE; Sean HIGGINS; Sarah DENNY; Benjamin OAKES; Emeric Jean Marius CHARLES
- Web page: https://patentgrep.com/patent/US20240254466A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 9/1007: {Methyltransferases (general) (2.1.1.)}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/86: Viral vectors
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 15/907: {in mammalian cells}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to gene repressor systems comprising catalytically-dead Class 2 CRISPR proteins and one or more transcription repressor domains linked to the catalytically-dead Class 2 CRISPR protein as a fusion protein, as well as a guide ribonucleic acid (gRNA); and methods of making and using same.

## Claims

### Claim 1

A gene repressor system comprising:
a. an RNA encoding a fusion protein, the fusion protein comprising:
i. a catalytically-dead Class 2, Type V CRISPR protein;
ii. a first transcription repressor domain comprising a sequence at least 70% identical to SEQ ID NO: 57755;
iii. a second transcription repressor domain; and
iv. a third transcription repressor domain, and
b. a guide ribonucleic acid (gRNA) capable of forming ribonucleoprotein (RNP) with the fusion protein, wherein the gRNA comprises a targeting sequence complementary to a target nucleic acid sequence of a gene targeted for repression, silencing, or downregulation.

### Claim 2 (depends on 1)

The gene repressor system of claim 1, wherein the second transcriptional repressor domain comprises a DNMT3A catalytic domain (DNMT3A CD).

### Claim 3 (depends on 2)

The gene repressor system of claim 2, wherein the DNTM3A CD comprises a sequence of SEQ ID NO: 59450, or a sequence having at least about 70% identity thereto.

### Claim 4 (depends on 1)

The gene repressor system of claim 1, wherein the third transcription repressor domain comprises a DNMT3L interaction domain (DNMT3L ID).

### Claim 5 (depends on 4)

The gene repressor system of claim 4, wherein the DNMT3L ID comprises a sequence of SEQ ID NO: 59625, or a sequence having at least about 70% identity thereto.

### Claim 6 (depends on 1)

The gene repressor system of claim 1, wherein the catalytically-dead Class 2, Type V protein is a catalytically dead Cas12e (dCasX).

### Claim 7 (depends on 1)

The gene repressor system of claim 1, wherein the catalytically-dead Class 2, Type V protein comprises a sequence of SEQ ID NO: 18, or a sequence having at least about 70% identity thereto.

### Claim 8 (depends on 7)

The gene repressor system of claim 7, wherein the catalytically-dead Class 2, Type V protein comprises a sequence of SEQ ID NOS: 18, 25, 59355, 59356, 59357 or 59358.

### Claim 9 (depends on 1)

The gene repressor system of claim 1, wherein the fusion protein comprises a fourth repressor domain, and wherein the fourth repressor domain comprises an ATRX-DNMT3-DNMT3L (ADD) domain.

### Claim 10 (depends on 9)

The gene repressor system of claim 9, wherein the C-terminus of the ADD domain is linked to the N-terminus of the second repressor domain, and wherein the second repressor domain comprises a DNMT3A catalytic domain.

### Claim 11 (depends on 1)

The gene repressor system of claim 1, wherein the fusion protein comprises one or more nuclear localization signals.

### Claim 12 (depends on 1)

The gene repressor system of claim 1, wherein the fusion protein comprises one or more linker sequences.

### Claim 13 (depends on 1)

The gene repressor system of claim 1, wherein the fusion protein comprises, from N to C terminus:
a. a nuclear localization signal (NLS), the second repressor domain, the third repressor domain, the catalytically-dead Class 2, Type V CRISPR protein, the first repressor domain and a second NLS; or
b. an NLS, the second repressor domain, the third repressor domain, the first repressor domain, the catalytically-dead Class 2, Type V CRISPR protein, and a second NLS,
wherein the first repressor domain, the second repressor domain, the third repressor domain, and the catalytically-dead Class 2, Type V CRISPR protein are separated by linker sequences, and
wherein:
i. the second transcriptional repressor domain comprises a DNMT3A catalytic domain (DNMT3A CD);
ii. the third transcription repressor domain comprises a DNMT3L interaction domain (DNMT3L ID); and
iii. the catalytically-dead Class 2, Type V protein is a catalytically dead Cas12e (dCasX).

### Claim 14 (depends on 1)

A lipid nanoparticle comprising the system of claim 1.

### Claim 15

A method of repressing transcription of a target nucleic acid sequence in a cell, comprising introducing into the cell a gene repressor system comprising:
a. an RNA encoding a fusion protein, the fusion protein comprising:
i. a catalytically-dead Class 2, Type V CRISPR protein;
ii. a first transcription repressor domain comprising a sequence at least 70% identical to SEQ ID NO: 57755;
iii. a second transcription repressor domain; and
iv. a third transcription repressor domain, and
b. a guide ribonucleic acid (gRNA) capable of forming ribonucleoprotein (RNP) with the fusion protein, wherein the gRNA comprises a targeting sequence complementary to a target nucleic acid sequence of a gene targeted for repression, silencing, or downregulation.

### Claim 16

A gene repressor system comprising:
a. an RNA encoding a fusion protein, the fusion protein comprising:
i. a catalytically-dead Class 2, Type V CRISPR protein;
ii. a first transcription repressor domain comprising a sequence at least 70% identical to SEQ ID NO: 57771 or SEQ ID NO: 57779;
iii. a second transcription repressor domain; and
iv. a third transcription repressor domain, and
b. a guide ribonucleic acid (gRNA) capable of forming ribonucleoprotein (RNP) with the fusion protein, wherein the gRNA comprises a targeting sequence complementary to a target nucleic acid sequence of a gene targeted for repression, silencing, or downregulation.

### Claim 17 (depends on 16)

The gene repressor system of claim 16, wherein the second transcriptional repressor domain comprises a DNMT3A catalytic domain (DNMT3A CD).

### Claim 18 (depends on 17)

The gene repressor system of claim 17, wherein the DNTM3A CD comprises a sequence of SEQ ID NO: 59450, or a sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto.

### Claim 19 (depends on 16)

The gene repressor system of claim 16, wherein the third transcription repressor domain comprises a DNMT3L interaction domain (DNMT3L ID).

### Claim 20 (depends on 19)

The gene repressor system of claim 19, wherein the DNMT3L ID comprises a sequence of SEQ ID NO: 59625, or a sequence having at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity thereto.

### Claim 21 (depends on 16)

The gene repressor system of claim 16, wherein the catalytically-dead Class 2, Type V protein is a catalytically dead Cas12e (dCasX).

### Claim 22 (depends on 16)

The gene repressor system of claim 16, wherein the catalytically-dead Class 2, Type V protein comprises a sequence of SEQ ID NO: 18, or a sequence having at least about 70% identity thereto.

### Claim 23 (depends on 22)

The gene repressor system of claim 22, wherein the catalytically-dead Class 2, Type V protein comprises a sequence of SEQ ID NOS: 18, 25, 59355, 59356, 59357 or 59358.

### Claim 24 (depends on 16)

The gene repressor system of claim 16, wherein the fusion protein comprises a fourth repressor domain, and wherein the fourth repressor domain comprises an ATRX-DNMT3-DNMT3L (ADD) domain.

### Claim 25 (depends on 24)

The gene repressor system of claim 24, wherein the C-terminus of the ADD domain is linked to the N-terminus of the second repressor domain, and wherein the second repressor domain comprises a DNMT3A catalytic domain.

### Claim 26 (depends on 16)

The gene repressor system of claim 16, wherein the fusion protein comprises one or more nuclear localization signals.

### Claim 27 (depends on 16)

The gene repressor system of claim 16, wherein the fusion protein comprises one or more linker sequences.

### Claim 28 (depends on 16)

The gene repressor system of claim 16, wherein the fusion protein comprises, from N to C terminus:
a. a nuclear localization signal (NLS), the second repressor domain, the third repressor domain, the catalytically-dead Class 2, Type V CRISPR protein, the first repressor domain and a second NLS; or
b. an NLS, the second repressor domain, the third repressor domain, the first repressor domain, the catalytically-dead Class 2, Type V CRISPR protein, and a second NLS,
wherein the first repressor domain, the second repressor domain, the third repressor domain, and the catalytically-dead Class 2, Type V CRISPR protein are separated by linker sequences, and
wherein:
i. the second transcriptional repressor domain comprises a DNMT3A catalytic domain (DNMT3A CD);
ii. the third transcription repressor domain comprises a DNMT3L interaction domain (DNMT3L ID); and
iii. the catalytically-dead Class 2, Type V protein is a catalytically dead Cas12e (dCasX).

### Claim 29 (depends on 16)

A lipid nanoparticle comprising the system of claim 16.

### Claim 30

A method of repressing transcription of a target nucleic acid sequence in a cell, comprising introducing into the cell a gene repressor system comprising:
a. an RNA encoding a fusion protein, the fusion protein comprising:
i. a catalytically-dead Class 2, Type V CRISPR protein;
ii. a first transcription repressor domain comprising a sequence at least 70% identical to SEQ ID NO: 57771 or SEQ ID NO: 57779;
iii. a second transcription repressor domain; and
iv. a third transcription repressor domain, and
b. a guide ribonucleic acid (gRNA) capable of forming ribonucleoprotein (RNP) with the fusion protein, wherein the gRNA comprises a targeting sequence complementary to a target nucleic acid sequence of a gene targeted for repression, silencing, or downregulation.
